M
MetLife, Inc.
MET · Financial Services
Q4 FY2025
Earning ended Dec 31, 2025Report generated Mar 10, 2026
MetLife's Pension Transfer Machine Is Worth More Than the Market Admits
Most investors see a commodity financial utility buffeted by interest rates; what they're missing is that MetLife is quietly becoming one of the two or three institutions globally capable of absorbing corporate America's defined benefit exodus — a structural franchise that compounds as plan sponsors get more desperate to de-risk.
Flowly Score
Apr 16 Close
+315%$77.09
Fair Value
$320.00
60
Averageat $77.09
Business Strength6/10
The employer benefits incumbency and pension risk transfer positioning are genuinely durable advantages, but ROE trending toward low double digits and the operational complexity that produced the 2018 pension tracking failure cap this at solidly average — good business, not a great one.
Financial Resilience6/10
Four years of float-driven cash generation well above reported earnings is the right structure for an insurer, but the 2025 OCF collapse against rising net income breaks the pattern in a way that demands explanation — the Piotroski 7 is reassuring but doesn't resolve that anomaly.
Growth & Trajectory6/10
Record pension risk transfer volumes and Asia's underpenetration represent genuine multi-decade tailwinds, but the core U.S. group benefits engine faces slow margin compression from benefits consultants and HR platform intermediation that will be a persistent drag on organic growth quality.
Valuation7/10at $70.77
Trading at a multiple that implies a sleepy utility with no growth optionality, while simultaneously holding the largest PRT pipeline in its history and growing adjusted EPS at double digits — the market is pricing the reported earnings volatility, not the underlying earnings power.
Risk5/10
GLP-1 actuarial uncertainty, HR software intermediation threatening switching cost economics, Japan currency exposure, and a governance history that revealed hidden operational liabilities combine into a risk profile that is manageable but not dismissible — this is not a set-and-forget holding.
The interaction between quality and price here is genuinely interesting: this is a B+ business trading at a price that assumes a C+ future. The adjusted earnings trajectory — up double digits in 2025, guided double digits again in 2026, with a record PRT year underneath it — tells a different story than the GAAP funhouse mirror that produced a 32x earnings multiple in 2023 before collapsing to single digits. The Brighthouse spinoff, P&C exit, and PineBridge acquisition form a coherent capital reallocation thesis toward higher-quality, more capital-light earnings — and the market hasn't repriced for the company that's emerging. The business is moving toward a model where three engines compound simultaneously: U.S. group benefits generating steady float and fee income, institutional PRT absorbing defined benefit runoff at attractive spreads, and Asia capturing life insurance penetration growth in markets where the middle class is expanding faster than domestic savings products can satisfy. The MetLife Investment Management separation is a credible attempt to surface fee income that was previously buried inside the insurance machinery — a value-unlocking move that mirrors what the best financial conglomerates have done by separating asset management from balance sheet risk. The single biggest specific risk is actuarial table disruption from GLP-1 drugs. If obesity-linked mortality improvements extend healthy lifespans materially beyond the tables embedded in MetLife's long-duration annuity book, reserve strain could arrive faster than management can hedge it — and unlike interest rate risk, which can be duration-matched, longevity improvement is a one-way ratchet with no natural offset on the liability side of the ledger.